Previous 10 | Next 10 |
2023-07-05 08:15:30 ET Impel Pharmaceuticals ( IMPL ) +36% . Wolfspeed ( WOLF ) +18% enter 10-year silicon carbide wafer supply agreement. Nocera ( NCRA ) +12% . Digital World Acquisition ( DWAC ) +10% reaches in-principle settleme...
Phase 2b FRONTIER 1 data presentation at World Congress of Dermatology highlights that a greater proportion of patients achieved 75, 90 and 100 percent improvement in skin clearance at week 16 in comparison to placebo Phase 3 development in moderate-to-severe plaque psoriasis and Phase 2b de...
2023-07-03 10:30:53 ET Gainers: Ensysce Biosciences ( ENSC ) +20% . Journey Medical ( DERM ) +20% . Ventyx Biosciences ( VTYX ) +16% . PainReform ( PRFX ) +12% . iCAD ( ICAD ) +7% . Losers: Protagonist Therapeutics ( PTG...
NEWARK, CA / ACCESSWIRE / June 9, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") announced today that Ronald Hoffman, MD, Icahn School of Medicine at Mount Sinai, provided a press briefing this morning on the late-breaking oral presentation abstract LB2710...
NEWARK, CA / ACCESSWIRE / June 6, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that a late-breaking abstract featuring blinded, randomized withdrawal data from the rusfertide (PTG-300) REVIVE Phase 2 study in polycythemia vera (PV) has been...
NEWARK, CA / ACCESSWIRE / June 1, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation and host one-on-one meetings with investors ...
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is the focus of IBN's latest stock spotlight. The company's shares have moved 6.75% on the day to $27.83. Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and ...
2023-05-25 17:18:09 ET Summary The stock of Protagonist Therapeutics, Inc. has more than doubled so far this year due to progress on a couple of fronts. Can the rally in the shares continue in 2023? An updated investment analysis follows in the paragraphs below. ...
2023-05-24 17:33:12 ET Summary Protagonist continues to quietly progress its pipeline, relying mainly on the polycythemia vera story to drive its business efforts. An ongoing phase 3 study will be the critical readout, but that doesn't mean that you need to wait for it. Other ...
2023-05-12 09:09:37 ET Protagonist Therapeutics ( NASDAQ: PTGX ) shared data from its partnership with Janssen Biotech, regarding the development of JNJ-2113. The pre-clinical data presented by Protagonist and Janssen Biotech on JNJ-2113 showed promising results in disease mod...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the BTIG Virtual Biotechnolog...